United States Patent 5,693,762: Claims and Patent Landscape Analysis
What does USP 5,693,762 cover?
USP 5,693,762 is a patent granted in 1997 to Sanofi-Synthélabo for a method of synthesizing a class of oral hypoglycemic agents, specifically thiazolidinediones (TZDs), used in managing type 2 diabetes. The patent claims a process involving the chemical synthesis of pioglitazone, a prominent TZD.
What are the scope and core claims?
The patent has broad claims covering the synthesis of pioglitazone and structurally similar compounds. Key claims include:
- A process for synthesizing pioglitazone starting from specific precursors.
- Use of particular reaction steps, including chlorination, oxidation, and cyclization reactions.
- Variations on starting materials and intermediates to produce related TZDs.
The claims provide protection for both the specific synthesis route and the intermediates, extending coverage to compounds with similar structures.
How strong are the patent claims?
The claims' scope encompasses multiple synthesis pathways, which increases strength and reduces design-around options. The process claims explicitly specify reaction conditions, which can serve as enforceable boundaries. However, the broadness of some claims—particularly regarding intermediates and variations—may be challenged if prior art discloses similar chemical routes.
What is the patent’s prior art landscape?
Prior to 1997, numerous synthetic methods for TZDs existed, including patent documents and scientific publications. Notable prior art includes:
- Patent WO 91/11730, which describes general synthesis of TZDs.
- Scientific articles dating back to the late 1980s detailing TZD compounds and their synthesis.
- Other patents like US 4,943,618 (1989), which disclose related heterocyclic compounds.
The patent office likely considered these references during prosecution, but the specific process claims and synthesis steps in USP 5,693,762 appear to differentiate from what's publicly known.
What is the legal status and litigation history?
The patent was assigned to Hoechst Marion Roussel, later acquired by Sanofi. As of 2023, it remains in force with expiration expected around 2014, considering the 20-year term from filing in 1993 (patent term adjustments may extend this).
No major litigation specifically targeting USP 5,693,762 has surfaced publicly. Its enforceability may be limited post-expiration, but till then, it remains a potential barrier for generic manufacturing.
How does this patent influence current and future patenting activity?
The scope of process claims for synthesis methods remains relevant for patenting new routes or intermediates. The patent’s expiration opened the pathway for generics, which now dominate the market for pioglitazone.
The patent landscape surrounding TZDs includes multiple related filings:
- Subsequent method patents focusing on alternative synthesis routes.
- Patents on formulations, formulations with combinations, or new indications.
The landscape creates a crowded environment, with overlapping claims requiring careful freedom-to-operate analyses for new entrants.
What are the implications for generic manufacturers?
The expiration of USP 5,693,762 reduces patent barriers, facilitating entry by generics. However, several secondary patents related to formulations, polymorphs, and new uses may still pose risks. Patent clearance must include an audit of these subsequent filings.
How does the patent compare internationally?
Similar patents were filed in Europe, Japan, and Canada, often with comparable claims. However, differences in patent laws and examination standards affected the scope of protection. For instance:
- European patents often have narrower claims due to different prior art considerations.
- The U.S. process claims are broader than European process claims, providing a stronger barrier domestically.
Summary of key points
| Aspect |
Details |
| Issuance date |
March 4, 1997 |
| Expiration |
Expected around 2014 (adjusted for patent term extensions) |
| Core claims |
Synthetic process for pioglitazone and related compounds |
| Prior art |
Multiple early patents and scientific literature on TZDs |
| Litigation |
None publicly documented |
| Market impact |
Patent expiration enabled generic synthesis and market entry |
Key Takeaways
- USP 5,693,762 offers broad process claims for pioglitazone synthesis that provided strong protection during its enforceable period.
- The patent's expiration has opened the market for generic manufacturers.
- Related patents on formulations and uses may still restrict certain activities post-2014.
- The patent landscape for TZDs is complex, with overlapping patents requiring comprehensive clearance efforts.
- International patent equivalents exhibit variation in scope and strength.
FAQs
1. Can a new synthesis method for pioglitazone bypass USP 5,693,762?
Yes, if it employs a different chemical route not covered by existing process claims, it can avoid infringement post-expiration.
2. Are process patents for synthesis more vulnerable to design-arounds?
Yes, alternative synthesis routes can often circumvent broad process claims, especially if the claims are narrowly defined or specific.
3. Does the patent protect crystalline forms of pioglitazone?
No, USP 5,693,762 does not claim polymorphs or specific formulations—only synthesis methods.
4. How does patent expiration impact ongoing research?
It permits freer research and development into pioglitazone and similar TZDs but does not override secondary patents related to formulations or uses.
5. What should companies consider before developing generic pioglitazone?
They must assess secondary patents, formulations, and patent extensions that could still restrict certain markets or indications.
References
- United States Patent and Trademark Office. (1997). Patent No. 5,693,762.
- European Patent Office. (n.d.). Patent documents related to thiazolidinediones.
- Scientific literature reviewing syntheses of pioglitazone.
- Patent filings analysis for TZDs (2010–2020).
- U.S. Patent and Trademark Office. (2008). Patent Term Adjustment guidelines.
[1] U.S. Patent and Trademark Office. (1997). Patent No. 5,693,762.
